

CORCEPT THERAPEUTICS INC  
Form 8-K  
June 04, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (date of earliest event reported): May 29, 2018**

**Corcept Therapeutics Incorporated**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
**of incorporation)**

**000-50679**  
**(Commission File**  
**Number)**  
**149 Commonwealth Drive**

**77-0487658**  
**(I.R.S. Employer**  
**Identification Number)**

Edgar Filing: CORCEPT THERAPEUTICS INC - Form 8-K

**Menlo Park, CA 94025**

**(Address of principal executive offices, with zip code)**

**(650) 327-3270**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.07 Submission of Matters to a Vote of Security Holders**

On May 29, 2018, we held our annual meeting of stockholders to consider and vote on proposals: 1) to elect seven directors to hold office until our 2019 annual meeting of stockholders and until their successors are elected and qualified, and 2) to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.

A total of 115,235,013 shares of Corcept Therapeutics Incorporated common stock held by stockholders of record at the close of business on April 18, 2018 were entitled to vote at the annual meeting. The total number of shares voted at the annual meeting was 108,841,664. The voting on the two matters is set forth below:

Proposal 1 Election of Directors. The following directors were elected to serve until our 2019 annual meeting of stockholders and until their successors are elected and qualified.

<b>Director</b>	<b>For</b>	<b>Withheld</b>	<b>Broker Non-Votes</b>
James N. Wilson	79,901,234	533,210	28,407,220
G. Leonard Baker, Jr.	79,906,775	527,669	28,407,220
Joseph K. Belanoff, M.D.	80,036,906	397,538	28,407,220
Daniel M. Bradbury	79,687,700	746,744	28,407,220
Reneé D. Galá	79,871,055	563,389	28,407,220
David L. Mahoney	77,158,123	3,276,321	28,407,220
Daniel N. Swisher, Jr.	80,092,227	342,217	28,407,220

Proposal 2 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.

For	107,929,017
Against	849,787
Abstain	62,860
Broker Non-Votes	N/A

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CORCEPT THERAPEUTICS  
INCORPORATED**

By: /s/ G. Charles Robb  
Name: G. Charles Robb  
Title: Chief Financial Officer and  
Secretary

Date: June 4, 2018